Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Explore this paper's citation graph
Summary
It is proposed that this form of therapy, judiciously applied, can normalize the tumor vasculature and improve the delivery of therapeutics.
- Type
- review
- Published
- 2001-09-01
- Cited by
- 2,270
- References
- 26
- OpenAlex
- https://openalex.org/W1603230122
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:29912002
Keywords
Cancer therapy, Antiangiogenic therapy, Medicine, Combination therapy, Angiogenesis
References
- Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A.
- Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts.
- Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications.
- Angiogenesis in cancer and other diseases
- Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer.
- Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
- Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.
- Targeting tumor vasculature with homing peptides from phage display.
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.
- An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma.
- Fractals and cancer.
- Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody.
- The next frontier of molecular medicine: Delivery of therapeutics
- Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha--> hypoxia response element--> VEGF cascade differentially regulates vascular response and growth rate in tumors.
- Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment.
- Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy.
- Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
- Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements.
- Genes expressed in human tumor endothelium.
- Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
Cited by
- A Model of Vascular Tumor Response to Chemotherapy Combined with Anti-Angiogenic Therapy
- ALK1 et BMP9 dans le remodelage vasculaire de la génétique humaine aux modèles murins
- Vascular targeting therapy: potential benefit depends on tumor and host related effects.
- Drug inhibition of angiogenesis.
- Hypoxia and hypoxia inducible factors (HIF) as important regulators of tumor physiology.
- Measuring tumour vascular response to antivascular and antiangiogenic drugs.
- Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.
- Structural mechanisms in the abolishment of VEGF-induced microvascular hyperpermeability by cAMP.
- The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice
- Molecular therapies for malignant glioma
- Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab
- Role of lymphangiogenesis in cancer.
- Antiangiogenesis: biology and utility in the treatment of gliomas
- Systemic Therapies in Hepatocellular Carcinoma
- Phase 1‐2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma
- Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repair
- Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography
- Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma
- The role of avastin in the management of recurrent glioblastoma.
- Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors
Related papers
- Progress in anti-angiogenesis cancer therapy and anti-angiogenesis drugs
- Targeting angiogenesis in cancer therapy.
- Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy
- Extracellular vesicle‐mediated regulation of tumor angiogenesis— implications for anti‐angiogenesis therapy
- Markers of Angiogenesis in Ovarian Cancer
- Antiangiogenic Cancer Therapy